Skip to Content Skip to Search

Investor and Analyst call from DREAMM-2 data

On Tuesday, 17 December 2019 at 17:00 GMT / 12:00 EST, Hal Barron, Chief Scientific Officer and President of R&D, Luke Miels, President Pharmaceuticals and Axel Hoos, SVP Oncology R&D hosted an investor/analyst conference call to discuss GSK’s pivotal DREAMM-2 data on belantamab mafodotin (GSK’916).

Back to top